---
source: https://alamarbio.com/alamar-biosciences-raises-128-million-in-oversubscribed-series-c-financing-to-accelerate-commercialization-of-its-proteomics-platform/
date: 2024-02-26
type: Company
---

# Alamar Biosciences Raises $128M Series C

Alamar Biosciences announced $128M Series C financing to accelerate commercialization of its proteomics platform.

## Funding Details

- **Amount:** $128M ($100M first close + $28M second close)
- **Total Raised:** ~$250M to date
- **Lead Investor:** Sands Capital
- **Board Addition:** Ian Ratcliffe (Sands Capital Executive Managing Partner)

## Use of Funds

- Grow commercial and customer support teams
- Drive market adoption
- Expand product menu

## NULISA Technology

NUcleic acid Linked Immuno-Sandwich Assay:
- Proteomic liquid biopsy platform
- Detects ~200 immune system cytokines, chemokines, related proteins
- Uses next-generation sequencing readout
- Sequential capture and release method purifies immune complex
- **10,000-fold improvement** in signal-to-noise
- **10-100x sensitivity** vs traditional immunoassays (attomolar detection)
- Extended dynamic range vs competitors

## Products

- **ARGO™ HT System:** Automated NULISA assays, <30 min hands-on time
- **NULISAseq™ Inflammation Panel 250:** Deep profiling of immune response

## Competitive Position

Attomolar sensitivity is 10-100x higher than Olink and SomaLogic, enabling detection of previously undetectable low-abundance proteins.
